Biomedcode has an active R&D program covering diverse areas including the:

• Development of new humanized model mice carrying selected human molecular targets that are best candidates for novel therapeutic approaches.  

• Standardization of induced models of disease in our humanized mouse models, mainly as co-development projects with our clients. Our recently developed disease models include CAIA in Tg1278TNFko transgenic mice and acute TNBS colitis in Tg197 transgenic mice.

• Development of pharmacogenomics and metabonomics approaches as tools that will complement future preclinical drug evaluation platforms.

• Participation in European and National Research Networks focusing on thematic areas such as Rheumatoid Arthritis, Inflammation and Cancer etc. In the last few years we have activelly participated in 4 large-scale European projects: the FP6 Network of Excellence MUGEN, and the FP7 Integrated projects Masterswitch, Inflacare and TARKINAID. Biomedcode is also a partner in the Greek consortium TheRAlead, which is funded through the SYNERGASIA national action, and aims to establish a multi-partner drug development pipeline towards novel therapeutic lead compounds for clinical evaluation.